# Live Event: April 2, 2025

New York Genome Center

101 6th Ave, New York, NY 10013



Lumanity | Cancer Progress


Cancer Progress started in 1989 with the goal of facilitating discussions of scientific progress in Oncology from a development, regulatory, clinical, commercial and investment lens. Cancer Progress features provocative, informative panel discussions with pivotal topics, frank discussions, vigorous debates, and audience engagement, to enable meaningful connections and meetings with innovators, developers, and investors.

We are thrilled to announce that on April 2, 2025, Cancer Progress returns as a live, in-person event in the heart of New York City! This streamlined, one-day conference promises a focused and impactful experience. Attendees can expect unparalleled insights, in-depth issue coverage, and exceptional networking opportunities. The conference's enduring success and value are driven by the expertise and reputation of its distinguished speaking faculty.

Join us for this dynamic gathering of experts for a thought-provoking exploration of the possibilities and challenges inherent in shaping the future of oncology.

**100% of proceeds from ticket sales and sponsorships will directly support the Damon Runyon Cancer Research Foundation and its mission to fund high-risk, high-reward cancer research.**

DAMON RUNYON
**CANCER RESEARCH**
FOUNDATION

At the Damon Runyon Cancer Research Foundation, we fund high-risk, high-reward cancer research. We identify and enable young scientists who are brilliant, brave and bold enough to go where others haven't. Since 1946, Damon Runyon has funded over 4,000+ scientists with an investment of over $430 million.

# Speakers & Moderators

**Dr. Qasim I Ahmad**
Chief Medical Officer,
IO Biotech

**Kaitlyn Andreano, PhD**
Engagement Manager,
Strategy Consulting
Lumanity

**Franscesca Barone, MD, PhD**
CSO,
Candel Therapeutics

**Laura Johnson, PhD**
Chief Operating Officer/
Scientific Officer, Head
of R&D
Verismo Therapeutics

**Lucy Kappel, PhD**
Vice President and
Head of Oncology
Business Development,
Regeneron Pharmaceuticals

**Llew Keltner, MD, PhD**
CEO,
EPISTAT

**Yung S. Lie, PhD**
President and CEO,
Damon Runyon

**Alan Bash**
President, Carvykti,
Legend Biotech

**Jeffrey Bockman, PhD**
EVP, Oncology
Lumanity

**Dennis Chang, PhD**
SVP,
Strategy Consulting
Lumanity

**Tom Murtagh**
Global Practice Lead,
Strategy & Insight
Lumanity

**Kelly Page, MBA**
SVP, Global Head of
Oncology Strategy and
Program Leadership
Arvinas

**Viraj Parekh, PhD**
Principal,
Strategy Consulting
Lumanity

**Michael Parisi, MBA**
Global Practice Lead,
Medical Strategy &
Communications
Lumanity

**JS Cleiftie, MS, MBA**
CBO and CFO,
NextRNA Therapeutics

**Ashlee Cramer**
Caregiver and Advocate
for Cancer and GvHD,
Social Influencer, Michael
and Mom Talk Cancer

**Michael Cramer**
Cancer Survivor, Patient
Advocate for Cancer and
GvHD, Social Influencer,
Michael and Mom
Talk Cancer

**Ed Saltzman**
Senior Strategic
Advisor,
Lumanity

**T.J. Sharpe**
Patient Engagement Expert,
Sharpe Patient Insights

**Lakshmi Srinivasan, PhD**
Executive Director,
Oncology Translational
Medicine
Moderna Therapeutics

**Martin Strebl-Bantillo, PhD**
Principal,
Strategy Consulting
Lumanity

**Kapil Dhingra, MD**
Managing Member,
KAPital Consulting

**Daniel Getts, PhD**
CEO and Co-Founder,
Myeloid Therapeutics

**Joe Guidi**
Vice President,
Global Medical
Early Differentiation
and Pipeline
Bristol Myers Squibb

**Dominique Verhelle, PhD, MBA**
Co-Founder and CEO,
NextRNA Therapeutics

**Angela Wheeler**
President, Insight
USA and Patient
CoE Lead
Lumanity

**John Wiggins**
Vice President,
Isotope Strategy
Lantheus

**Kate Yen, PhD**
Founder and CEO,
Auron Therapeutics

**Amy Han**
Vice President,
Global Commercialization,
Solid Tumors
Genmab

**Adriana Herrera**
CEO,
Pierre Fabre
Pharmaceuticals, Inc

**Axel Hoos, MD, PhD**
Former CEO,
Scorpion Therapeutics

# Agenda

8:15 AM - 9:00 AM

## Registration and Morning Networking

Attendees check in at registration table, and enjoy light morning refreshments with coffee and tea.

9:00 AM - 9:15 AM

## Opening Address

**Jeffrey Bockman, PhD**
EVP, Oncology
Lumanity

**Tom Murtagh**
Global Practice Lead,
Strategy & Insight
Lumanity

9:15 AM - 10:30 AM

## Patient Voices: Shaping the Future of Cancer Care

As cancer treatments evolve, so do the needs and expectations of people living with cancer. Hear from the most important PhDs in the room – those with a Personal History of the Disease.

- What do these PhDs think about the development of novel, innovative therapies in a world where so many struggle to access and afford those already in existence?
- Discuss the importance of "patient-centered clinical endpoints" versus "tumor-centered clinical endpoints."
- Understand what "durable, long-term remission" means to them and what potential QoL trade-offs are reasonable risks
- Learn from their experience the value to be gained by developing oncology treatments with their needs in mind

**Ashlee Cramer**
Caregiver and Advocate for Cancer and GvHD, Social Influencer, Michael and Mom Talk Cancer

**Michael Cramer**
Cancer survivor, Patient Advocate for Cancer and GvHD, Social Influencer, Michael and Mom Talk Cancer

**T.J. Sharpe**
Patient Engagement Expert,
Sharpe Patient Insights

**Angela Wheeler**
President, Insight USA and Patient CoE Lead
Lumanity

10:30 PM - 10:45 PM

## Coffee Break

10:45 AM - 12:00 PM

## Back to the Future: Next-Generation Platforms

While the past two years have been challenging for many biotechs, especially Oncology-focused ones, the industry hunger for innovation in cancer – new therapeutic modalities, novel MOAs – continues unabated as the unmet needs among most cancer patients remains for achieving durable, long-term remissions. While the focus continues to be on the hot space of ADCs, there is a resurgence of interest in Adoptive Cell Therapy, and in Bispecifics, as well as Vaccines, but also truly new spaces of cancer biology. A common theme among these includes multi-targeting to improve both efficacy and safety, if not to address the inherent heterogeneity in cancer. This panel will explore, among other topics:

- How can early stage biotechs best show the value proposition of their program or platform?
- How can they balance technical and commercial risk?
- What do larger partners want to see from an early program or technology?
- How are larger players navigating the surplus of innovation in the current market?

**Kaitlyn Andreano, PhD**
Engagement Manager,
Strategy Consulting
Lumanity

**Franscesca Barone, MD, PhD**
CSO,
Candel Therapeutics

**Jeffrey Bockman, PhD**
EVP, Oncology
Lumanity

**Kapil Dhingra, MD**
Managing Member,
KAPital Consulting

**Amy Han**
Vice President, Global Commercialization, Solid Tumors
Genmab

**Axel Hoos, MD, PhD**
Former CEO,
Scorpion Therapeutics

**Lucy Kappel, PhD**
Vice President,
Head of Oncology Business Development,
Regeneron Pharmaceuticals

**Lakshmi Srinivasan, PhD**
Executive Director,
Oncology Translational Medicine
Moderna Therapeutics

**Dominique Verhelle, PhD, MBA**
Co-Founder and CEO,
NextRNA Therapeutics

12:00 PM - 1:00 PM

## Lunch and Networking

# Agenda

1:00 PM - 2:15 PM

## Commercializing Uphill: Realizing Challenging Propositions

Some exciting new modalities, such as RLT and Cell therapies, required a breaking with traditional distribution models, changes to the infrastructure at provider institutions, new payment models, and many other adjustments to “business as usual”. This panel will explore:

- Innovative approaches to facilitate “plasticity” at provider institutions to adopt new technologies
- Limits to scalability of these approaches, and potential ways of broadening their reach beyond current limits
- Considerations about how far innovation can push the current system before a fundamental change in the delivery approach is required (i.e. not every patient can realistically receive cell therapy or RLT currently due to system constraints- how far are we from a breaking point?)

**Alan Bash**
President, Carvykti
Legend Biotech

**Adriana Herrera**
CEO,
Pierre Fabre
Pharmaceuticals, Inc

**Laura Johnson, PhD**
Chief Operating Officer, Scientific Officer, Head of R&D
Verismo Therapeutics

**Ed Saltzman**
Senior Strategic Advisor,
Lumanity

**Martin Strebl-Bantillo, PhD**
Principal,
Strategy Consulting
Lumanity

**John Wiggins**
Vice President,
Isotope Strategy
Lantheus

2:15 PM - 3:30 PM

## Breaking with Dogmas: What is Holding us Back?

The majority of oncology drug development follows a well trodden path: seeking early signals in the form of tumor shrinkage in preclinical models and heavily pretreated patient populations, seeking first approval for monotherapy in late-line settings, and then moving earlier and in combinations. But this is a decades-old paradigm with its roots in cytotoxic chemotherapy. To what extent is this dogmatic approach holding us back from transformational innovations? Could blazing different trails lead to greater impact than ever before? Examples of topics that this panel may explore:

- What paradigms of oncology treatment are we neglecting or hampering by adhering to current dogmas? (E.g.: Early interception/prevention? Transforming cancer into a chronically manageable disease? Gene therapy of cancer?)
- What do we need to change to establish these new paradigms? (E.g.: New endpoints for signal-finding and proof-of-concept? New approaches to patient selection? New models of cross-company collaboration? New methodologies for opportunity assessment and valuation?)

**Dr. Qasim I Ahmad**
Chief Medical Officer,
IO Biotech

**Dennis Chang, PhD**
SVP,
Strategy Consulting
Lumanity

**Kapil Dhingra, MD**
Managing Member,
KAPital Consulting

**Daniel Getts, PhD**
CEO and Co-Founder,
Myeloid Therapeutics

**Joe Guidi**
Vice President,
Global Medical
Early Differentiation and Pipeline
Bristol Myers Squibb

**Kate Yen, PhD**
Founder and CEO,
Auron Therapeutics

3:30 PM - 3:45 PM

## Coffee Break

# Agenda

3:45 PM - 5:00 PM

## Boats and the Tide: Changes in the Pharma Ecosystem

The race to develop new, innovative medicines that deliver value has never been greater. External market pressures from payers and providers to show value and fill unmet needs continues to drive and shift pipeline investments and drug development pathways for large pharma. Furthermore, the introduction of the IRA has forced drug developers to relook at their approach to develop rationally designed drugs to address the needs of niche/biomarker driven populations and relook at developing innovative medicines and biologics that treat broader populations.

This session will explore the evolving dynamics of innovative science, breakthrough drug development and practice economics to address and fund these innovations. We will dig deep into the relationship and co-dependence between large pharma and innovative biotech to accelerate product pipelines and deliver value to patients and to the market.

**JS Cleiftie, MS, MBA**
CBO and CFO,
NextRNA Therapeutics

**Axel Hoos, MD, PhD**
Former CEO,
Scorpion Therapeutics

**Llew Keltner, MD, PhD**
CEO,
EPISTAT

**Kelly Page, MBA**
SVP, Global Head of Oncology Strategy and Program Leadership
Arvinas

**Michael Parisi, MBA**
Global Practice Lead, Medical Strategy & Communications
Lumanity

**Ed Saltzman**
Senior Strategic Advisor,
Lumanity

5:00 PM – 5:30 PM

## Closing Remarks

**Yung S. Lie, PhD**
President and CEO,
Damon Runyon

**Martin Strebl-Bantillo, PhD**
Principal,
Strategy Consulting
Lumanity

5:30 PM - 7:30 PM

## Reception and Networking



Lumanity

# Strategy Consulting

We blend essential cross-functional scientific, clinical, regulatory, and commercial perspectives to help our clients navigate the web of complex decisions and position their assets and organizations for success.

### Asset & Organizational Strategy

**Navigate the complexity of commercialization with confidence.** We work across therapeutic areas and throughout the product lifecycle to develop strategic solutions, evaluate opportunities, and transform ideas into action.

- Opportunity identification and quantification
- Early development feasibility assessment
- Indication prioritization and sequencing
- Target product profile development
- Value proposition development and early access strategy
- Early commercialization planning

### Medical Affairs

**Strengthen your engagement and communication with stakeholders, including investors, trial sites, and patients.** With our guidance, we can solidify your scientific story, build advocacy, and accelerate trial enrollment.

- Scientific narrative development
- Key thought leader (KTL) identification and advocacy development strategy
- Competitive analysis and unmet need assessment
- Patient enrollment strategy and execution
- Trial site analysis and validation
- Data and evidence gap analysis

### Clinical & Regulatory

**Accelerate your path to market with our expert-driven, integrated solutions.** We leverage deep clinical, regulatory, and compliance expertise to streamline the development of your innovative assets.

- Asset selection and strategic planning
- Integrated development planning
- Clinical development and regulatory strategy
- Health authority meetings, submissions, and interactions
- Claim maximization
- Expert scientific, regulatory, and development guidance and representation
- Development optimization and disruption

## Partner with us

**Alex Gant**
Global Marketing Director
alex.gant@lumanity.com

**Ting Sung**
Sr. Manager, Corporate Communications
ting.sung@lumanity.com

# Thank you to our 2025 Sponsors

Fundraising for Timmerman Traverse. All proceeds go to Damon Runyon Cancer Research Foundation.

Bristol Myers Squibb™

BIOTECH

Arsenal Capital Partners

Lumanity

BioInvent

NURIX™

## Tell us what you think

Participant Feedback Survey

Lumanity | Cancer Progress

lumanity.com/cancer-progress